Molecular Templates (MTEM) Receives Daily News Sentiment Score of 0.17
News articles about Molecular Templates (NASDAQ:MTEM) have trended somewhat positive on Friday, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Molecular Templates earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.1497807407417 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several brokerages recently weighed in on MTEM. Zacks Investment Research raised shares of Molecular Templates from a “sell” rating to a “hold” rating in a research report on Thursday. ValuEngine downgraded shares of Molecular Templates from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $5.20.
Shares of MTEM traded up $0.24 on Friday, hitting $5.67. 1,059,883 shares of the stock traded hands, compared to its average volume of 77,902. Molecular Templates has a one year low of $3.85 and a one year high of $13.25. The company has a quick ratio of 4.54, a current ratio of 4.54 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $140.45 million, a P/E ratio of -2.69 and a beta of 3.01.
About Molecular Templates
Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma.
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.